Wan-Chun Wu, Wei Zhao, Sheng Li, Department of Gastro-enterology, Yijishan Hospital, Wuhu 241000, Anhui Province, China
Correspondence to: Wan-Chun Wu, Department of Gastro-enterology, Yijishan Hospital, Wuhu 241000, Anhui Province, China. email@example.com
Received: February 14, 2007 Revised: November 22, 2007
AIM: To explore the relationship between small intestinal motility and small intestinal bacteria overgrowth (SIBO) in Nonalcoholic steatohepatitis (NASH), and to investigate the effect of SIBO on the pathogenesis of NASH in rats. The effect of cidomycin in alleviating severity of NASH is also studied.
METHODS: Forty eight rats were randomly divided into NASH group (n = 16), cidomycin group (n = 16) and control group (n = 16). Then each group were subdivided into small intestinal motility group (n = 8), bacteria group (n = 8) respectively. A semi-solid colored marker was used for monitoring small intestinal transit. The proximal small intestine was harvested under sterile condition and processed for quantitation for aerobes (E. coli) and anaerobes (Lactobacilli). Liver pathologic score was calculated to qualify the severity of hepatitis. Serum ALT, AST levels were detected to evaluate the severity of hepatitis.
RESULTS: Small intestinal transit was inhibited in NASH group (P < 0.01). Rats treated with cidomycin had higher small intestine transit rate than rats in NASH group (P < 0.01). High fat diet resulted in quantitative alterations in the aerobes (E. coli) but not in the anoerobics (Lactobacill). There was an increase in the number of E. coli in the proximal small intestinal flora in NASH group than in control group (1.70 ± 0.12 log10 (CFU/g) vs 1.28 ± 0.07 log10 (CFU/g), P < 0.01). TNF-a concentration was significantly higher in NASH group than in control group (1.13 ± 0.15 mmol/L vs 0.57 ± 0.09 mmol/L, P < 0.01). TNF-a concentration was lower in cidomycin group than in NASH group (0.63 ± 0.09 mmol/L vs 1.13 ± 0.15 mmol/L, P < 0.01). Treatment with cidomycin showed its effect by significantly lowering serum ALT, AST and TNF-a levels of NASH rats.
CONCLUSION: SIBO may decrease small intestinal movement in NASH rats. SIBO may be an important pathogenesis of Nash. And treatment with cidomycin by mouth can alleviate the severity of NASH.
© 2008 WJG. All rights reserved.
Key words: Nonalcoholic steatohepatitis; Small intestinal motility; Small intestinal bacteria overgrowth treatment
Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol 2008; 14(2): 313-317
With much more prevalence of nonalcoholic fatty liver disease (NAFLD) than previously thought noticed, there has been an explosion on the research of pathogenesis of NAFLD. NAFLD may develop into cirrhosis of liver through NASH, in some cases, to hepatocellular carcinoma[1-5], Insulin resistance and peroxidative injury were thought to place an important role in the pathogenesis of NASH[6-12]. But there are still other mechanisms that can trigger and maintain NASH[13-18]. Small intestinal bacterial overgrowth has been reported to place a role in the pathogenesis of NASH, endotoxin and TNF-a being the possible mediator[19-21]. But contrary to this hypothesis, in another study, antibiotic treatment did not normalize aminotransferase levels in NASH patients. Therefore more study is needed on the influence of SIBO on the pathogenesis of NASH and the curative effect of antibiotic on NASH. Alejandro S found that prolonged Orocecal Transit Time (OCTT) in NAFLD patients coexist with SIBO. It is generally thought that prolonged OCTT is the cause of SIBO. But it is not clear if alteration of intestinal motility is a cause or a consequence of SIBO.
We established an NASH animal model by high fat diet to explore the relationship between intestinal motility and SIBO in NASH. The relationship between SIBO and NASH, and the curative effect of antibiotic on NASH were also studied.
MATERIALS AND METHODS
Forty eight male SD strain rats were used in this study. Rats were housed individually in cages at constant room temperature in a 12-h light/dark cycle and had free access to laboratory feed and water. Semi-solid colored marker (carbon-ink 85%, gum acacia 10%, activated charcoal 5%) was made in our laboratory. Bacteria evaluation kit (API 20) was purchased from French Biomerieux CO. TNF-a kit was purchased from Technology Development Center of the General Hospital of PLA.
Establishment of animal mode
Forty eight SD rats were randomly divided into NASH group, cidomycin group and control group. Each group were subdivided into small intestinal motility group (n = 8) and bacteria group (n = 8) respectively. Rats in NASH group and cidomycin group were fed with high fat diet that was made by ordinary diet (88%) plus fat (10%) and cholesterol (2%) (supported by Qinglongshan Nursery) Rats in control group were fed with ordinary diet (supported by Qinglongshan Nursery). Furthermore, rats in cidomycin group were treated with cidomycin (12Mu ig qd) after eight weeks of high fat diet while those in the other two groups were treated with isotonic Na chloride (1 mL/d ig qd). At the end of the twelfth week, when the rats in NASH group and cidomycin group had received high fat diet for 12 wk, all the rats were killed, the serum levels of aminotransferase, TNF-a were tested and the histology of liver specimen was observed by H&E staining.
Measurement of small intestinal transit
Rats in small intestinal motility group was deprived of food for 24 h and water for 12 h prior to measurement of small intestinal transit. Then 1.0 mL semi-solid colored marker was administered into stomach by orogastric gavage. Twenty minutes later, the rat was killed, abdomen was opened and small intestine was dissected. The distance traveled by the marker was calculated. The small intestinal transit was represented by ratio of the distance traveled by the marker to the total length of the small intestine.
The liver pathologic score was calculated according to the lecture: Inflammation in portal canal area was denoted by “P”, inflammation inside lobules of liver by “L”, piecemeal necrosis by “PN” and bridging necrosis by “BN”. According to the severity of inflammation and necrosis, every item was scored from one to four. The total score of the liver inflammation was “P+L+2PN+2BN”.
Measurement of small intestinal bacteria
Rats in the bacteria group was deprived of food for 24 h and water for 12 h prior to measurement of small intestinal bacteria. Then the rat was killed, the abdomen was opened and the proximal small intestine was harvested under sterile condition. A two-centimeter-long small intestine was dissected from the point about ten centimeters from pylorus, then rinsed with sterile saline thrice, and next, the leftover was sucked by sterile filter paper. After weighing, the leftover and 2 mL sterile saline were placed in a sterile glass homogenizer and homogenized. The homogenate was diluted with sterile saline at the ratio of 1:1, then, 100 mL dilution was plated on SS agar (E. coli) and MRS agar (Lactobacilli) respectively. The quantity of E. coli was determined after 24 h of aerobic cultivation at 37℃. While the quantity of Lactobacilli was determined after 48 h of anaerobic cultivation at 37℃. The number of Colony forming units (CFU) of bacteria was quantified. The quality of aseptic manipulation was evaluated by inoculating swab of abdominal cavity on sheep-blood agar. The serum TNF-a levels were detected, using radio-immunity method, in our laboratory.
Throughout this report, data were expressed as mean ± SD. Experimental results were analyzed by one-factor analysis of variance. P < 0.05 was considered statistically significant.
The weight of the model group rise vs controls was 455.38± 11.48g vs 395.38 ± 10.91 g, P < 0.05.
Pathologically a NASH model has been successfully made (Figure 1).
TNF-a, liver pathologic score, serum ALT and AST levels are higher in the NASH group than in the other two groups indicating a NASH model has been successfully made (P < 0.01, P < 0.01, P < 0.05). There are no statistical differences between the control group and the cidomycin group in serum TNF-a level. Liver pathologic score, serum ALT and AST levels are higher in cidomycin group than in control group (P < 0.01) (Table 1).
The number of E. coli in the proximal small intestinal flora are more in the NASH group than in the control group and cidomycin group (P < 0.01, P < 0.01). Small intestinal motility are weaker in NASH group than in control group and cidomycin group (P < 0.01, P < 0.01).The number of E. coli are less in cidomycin group than in control group (P < 0.05). There are no statistic difference in small intestinal motility between control group and cidomycin group. There are no statistical differences in the number of Lactobacilli between every two groups of the three (Table 2).
It was found that NASH coexist with SIBO[19,24]. In our study excessive multiplication of E. coli and increased serum level of aminopherase coexist in NASH rats, that was consistent with previous studies. We thought that SIBO is an important, though not the only, pathogenesis of NASH by the fact that antibacterial treatment can alleviate the severity of NASH. We also found the level of aminopherase went up and down with serum level of TNF-a. It strongly supported TNF-a to be an important mediator in the promotion of NASH by SIBO. In our study, rats treated with cidomycin had a serum level of aminopherase slightly higher than controls and a serum level of TNF-a similar to controls. The reason or this phenomenon might be that TNF-a is not the only mediator. Generally endotoxemia was thought to be a link between SIBO and elevated TNF-a level[19,20]. But Wigg A J observed that serum levels of TNF-a and endotoxin were not parallel in NASH patients. Given the disadvantage of clinical trials to control experimental conditions, and the disadvantage of C14 breath test in identification of bacteria, animal experiments are necessary to find the link between SIBO and NASH. Our study found a significant increase in the number of E. coli, a widely known source of endotoxin, in the proximal small intestinal flora in NASH group. It might support endotoxin to be the promoter to TNF-a in NASH.
With respect to the causality between SIBO and small intestinal motility in NASH, ALEJANDRO-S found that delayed intestinal transit coexist with SIBO in patients effected by NASH. We also observed that NASH rats suffered both delayed intestinal motility and an increase in intestinal E. coli. It is widely believed that delayed intestinal motility could cause SIBO. Leveau P et al noticed a delay in intestinal transit time, appeared as an early event in acute pancreatitis, preceding intestinal bacterial overgrowth, and suggested that impairment in intestinal motility probably played a role in the development of bacterial overgrowth. Gangarosa demonstrated that intestinal motility served as a normal cleansing mechanism of the intestine, and drugs that decreased this motility might facilitate replication of pathogens and their attachment to or invasion of the intestinal tissue. Nieuwenhuijs et al[28,29], clarified the role of the migrating motor complex (MMC) in the regulation of small intestinal microflora by the fact that the disruption of MMC with morphine promotes duodenal bacterial overgrowth. Since MMC can also coordinate with the movement of the pylorus, gut and cholecyst, the alteration of MMC necessarily has an influence on the secretion of bile (the inhibiter of gram-negative bacilli). MMC might influence intestinal bacteria via another mechanism. Grzesiuk et al, demonstrated that intestinal bacteria, particularly those adhering to intestinal epithelial cells, were exposed to electric fields and currents generated by the muscular activity of the small intestine and that the myoelectrical activity of the duodenum, through action on cell membrane, can affect cell division of intestinal bacteria.
Though it is generally believed that insulin resistance can explain the delay of small intestinal motility in NASH, and abnormality of intestinal bacteria may be caused by delayed intestinal motility, in our experiment, treatment with antibiotics improved the abnormality of small intestinal motility in NASH rats, indicating that small intestinal bacterial can also regulate intestinal motility in NASH rats. The interpretation may be founded on the influence microflora has on intestinal smooth muscle cell myoelectricity action. Huseby et al demonstrated that after introduction of conventional intestinal microflora the interval between activity fronts of the MMC in proximal jejunum of germ-free rats was reduced. Sjogren et al reported that bacterial adherence to the intestinal mucosa appeared to be important in eliciting the abnormal myoelectric responses. Different intestinal bacterial genus may have different influence on intestinal motility. E. coli adherence to intestinal mucosa delayed spike bursts, reduced the frequency and amplitude of the intestinal contractions and inhibit small intestinal transit. while Lactobacillus promoted regular spike burst activity, reduced the MMC period and accelerated small intestinal transit. In our study the overgrowth of E. coli coexist with the reduction of small intestinal motility, and the elimination of E. coli could increase the small intestinal motility, strongly supporting E. coli to be an important mediator in the small intestinal motility in NASH rats. In our study Lactobacillus didn’t change according to high fat diet or cidomycin treatment, indicating Lactobacillus may not be important in the pathogenesis of NASH.
The results of this study suggest that SIBO may be not only the result of but also a promoter to delayed intestinal motility in NASH. There might be a vicious circle between SIBO and delayed intestinal motility in NASH rats. SIBO can trigger NASH via TNF-a, and treatment with cidomycin orally can alleviate the severity of NASH.
While once considered a benign process, nonalcoholic steatohepatitis (NASH) has been found to lead to cirrhosis and, in some cases, to hepatocellular carcinoma. The mechanisms underlying disease development and progression are awaiting clarification; however the finding that not all patients with steatosis develop hepatic inflammation and hepatocellular damage has led to the hypothesis that different pathogenic factors lead firstly to hepatic steatosis and secondly to hepatic damage (“the second hit”). Insulin resistance and obesity-related inflammation, among other possible genetic, together with oxidative stress, microcirculation disturbance, malnutrition are thought to play a key role in the second stage. People also found that small intestinal bacteria overgrowth (SIBO) may also play a role in the process of NASH. Some people think the medium of TNF-a to be an endotoxin, but all people do not accept this.
Great effort has been and is still being done to clarify all the possible mechanism in the development of NASH, The source and pathogenesis of mediators of inflammation in the process has been the hotspot. People also want to know if it can act as a target point in the treatment of NASH.
Innovations and breakthroughs
In this article the relationship between the small bowel moment and SIBO is studied. And the cidomycin was first studied for the treatment of NASH.
This article helps to understand the process of SIBO leading to NASH, and suggests that Cidomycin might be useful in the treatment of NASH. Since there might be a vicious circle between SIBO and delayed intestinal motility, the treatment of accelerator of intestinal motility might also be useful.
NASH: A liver disease, which resembles alcoholic liver disease consists of steatosis plus inflammation, necrosis, and fibrosis while lack of history of drinking. SIBO: Small intestinal bacterial overgrowth.
This article tries to study the relationship between SIBO and delayed intestinal motility in NASH rats and suggest that cidomycin might be effective in the treatment of NASH. But the conclusion needs further probation in future clinical study before clinical application.
1 Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-588 PubMed
2 Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80 PubMed
3 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110 PubMed
4 Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719 PubMed
5 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 PubMed
6 Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 PubMed
7 Agarwal N, Sharma BC. Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol Res 2005; 33: 92-96 PubMed
8 Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379 PubMed
9 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54 PubMed
10 Choudhury J, Sanyal AJ. Insulin resistance in NASH. Front Biosci 2005; 10: 1520-1533 PubMed
11 Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report. Indian J Gastroenterol 2004; 23: 12-15 PubMed
12 Rodriguez-Hernandez H, Gonzalez JL, Rodriguez-Moran M, Guerrero-Romero F. Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res 2005; 36: 362-366 PubMed
13 Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429 PubMed
14 Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075 PubMed
15 Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand J Gastroenterol 2007; 42: 1095-1101 PubMed
16 Zhao CY, Wang YD, Zhou JY, Jia B, Cui JF. An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis. Zhonghua Ganzangbing Zazhi 2007; 15: 450-455 PubMed
17 Malaguarnera L, Rosa MD, Zambito AM, dell'Ombra N, Marco RD, Malaguarnera M. Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 2006; 101: 2060-2069 PubMed
18 Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S, Enomoto N, Takei Y, Sato N. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 2005; 33: 151-154 PubMed
19 Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology 1989; 36: 349-351 PubMed
20 Zhao LF, Jia JM, Han DW. The role of enterogenous endotoxemia in the pathogenesis of non-alcoholic steatohepatitis. Zhonghua Ganzangbing Zazhi 2004; 12: 632 PubMed
21 Fan JG, Xu ZJ, Wang GL, Ding XD, Tian LY, Zheng XY. Change of serum endotoxin level in the progress of nonalcoholic steatohepatitis in rats. Zhonghua Ganzangbing Zazhi 2003; 11: 73-76 PubMed
22 Soza A, Riquelme A, Gonzlez R, Alvarez M, Prez-Ayuso RM, Glasinovic JC, Arrese M. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50: 1136-1140 PubMed
23 Fan JG, Xu ZJ, Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol 2005; 11: 5053-5056 PubMed
24 Riordan SM, Duncombe VM, Thomas MC, Nagree A, Bolin TD, McIver CJ, Williams R. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. Gut 2002; 50: 136-138 PubMed
25 Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211 PubMed
26 Leveau P, Wang X, Soltesz V, Ihse I, Andersson R. Alterations in intestinal motility and microflora in experimental acute pancreatitis. Int J Pancreatol 1996; 20: 119-125 PubMed
27 Gangarosa EJ. Recent developments in diarrheal diseases. Postgrad Med 1977; 62: 113-117 PubMed
28 Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg 1998; 228: 188-193 PubMed
29 Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A, Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999; 29: 33-40 PubMed
30 Grzesiuk E, Laubitz D, Wojcik-Sikora A, Zabielski R, Pierzynowski SG. Influence of intestinal myoelectrical activity on the growth of Escherichia coli. Bioelectromagnetics 2001; 22: 449-455 PubMed
31 Husebye E, Hellstrom PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G368-G380 PubMed
32 Sjogren RW, Sherman PM, Boedeker EC. Altered intestinal motility precedes diarrhea during Escherichia coli enteric infection. Am J Physiol 1989; 257: G725-G731 PubMed
S- Editor Liu Y L- Editor Alpini GD E- Editor Lu W